• Users Online: 97
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2020  |  Volume : 17  |  Issue : 2  |  Page : 209-214

Outcome of response of multiple myeloma to induction treatment in kurdistan region of Iraq


1 Department of Hematology, Hiwa Cancer Hospital, University of Sulaymaniyah, Sulaymaniyah, Iraq
2 Department of Medicine, College of Medicine, Hawler Medical University, Erbil, Iraq
3 Department of Pathology, College of Medicine, University of Sulaymaniyah, Sulaymaniyah, Iraq
4 Department of Pathology, College of Medicine, University of Duhok, Kurdistan Region, Iraq
5 Department of Pathology, College of Medicine, Hawler Medical University, Erbil, Iraq
6 Department of Medicine, College of Medicine, University of Duhok, Kurdistan Region, Iraq
7 Department of Hematology, Nanakali Hospital, Erbil, Iraq

Correspondence Address:
Akram Mahmood Mohammed
Department of Hematology, Hiwa Cancer Hospital, Sulaymaniyah, Kurdistan Region
Iraq
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/MJBL.MJBL_25_20

Get Permissions

Background: Nowadays, the therapy of multiple myeloma (MM) has successful and hopeful outcomes. Worldwide, various treatment regimens are prescribed by clinical hematologists. Objectives: The objective was to evaluate response to induction treatment and survival of MM patients treated with various treatment regimens in the Kurdistan Region of Iraq (KRI). Materials and Methods: A total of 114 patients in the KRI were included in a retrospective study through the period of January 1, 2010, to September 31, 2019. The diagnosis of MM was confirmed using the International Myeloma Working Group (IMWG) guidelines. The treatment responses were assessed according to the IMWG response criteria. Results: Complete response among the MM patients was 35.7%, very good partial response (VGPR) was 28.7%, partial response reached 9.1%, and stable disease reached 16.5%. The Kaplan–Meier curve showed those with VGPR had better survival than the rest of the response categories. Meanwhile, there was a significant association between MM patients on bortezomib and dexamethasone treatment regimen and complete remission was noticed (P = 0.02). Conclusions: The combination therapy of bortezomib and dexamethasone is effective in achieving a better response to treatment and good survival than other therapy regimens.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed64    
    Printed2    
    Emailed0    
    PDF Downloaded16    
    Comments [Add]    

Recommend this journal